Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Total Liabilities (2020 - 2025)

Bioventus (BVS) has disclosed Total Liabilities for 6 consecutive years, with $455.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 16.09% year-over-year to $455.1 million, compared with a TTM value of $455.1 million through Dec 2025, down 16.09%, and an annual FY2025 reading of $455.1 million, down 16.09% over the prior year.
  • Total Liabilities was $455.1 million for Q4 2025 at Bioventus, down from $535.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.0 billion in Q4 2022 and bottomed at -$233.3 million in Q3 2023.
  • Average Total Liabilities over 5 years is $519.9 million, with a median of $559.6 million recorded in 2024.
  • The sharpest move saw Total Liabilities surged 401.34% in 2021, then crashed 133.89% in 2023.
  • Year by year, Total Liabilities stood at $618.2 million in 2021, then skyrocketed by 55.36% to $960.4 million in 2022, then crashed by 38.59% to $589.8 million in 2023, then fell by 8.04% to $542.4 million in 2024, then fell by 16.09% to $455.1 million in 2025.
  • Business Quant data shows Total Liabilities for BVS at $455.1 million in Q4 2025, $535.5 million in Q3 2025, and $505.5 million in Q2 2025.